Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
November 16, 2017
AbbVie

AbbVie to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference

Peter Hartman spoke to Rapidus about investment promotion and the new joint microbiome project with Copenhagen Capacity and Invbest in Skåne.

AbbVie to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference

-
AbbVie
-
November 16, 2017

NORTH CHICAGO, Ill., Nov. 15, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Evercore ISI Biopharma Catalyst/Deep Dive Conference on Wednesday, November 29, 2017. Bill Chase, executive vice president and chief financial officer, will present at 7 a.m. Central time.

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVieAbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience.  In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.

SOURCE AbbVie

Contact(s)
AbbVie 
Media
Adelle Infante
adelle.infante@abbvie.com
(847) 938-8745
AbbVie 
Investors
Liz Shea
liz.shea@abbvie.com
(847) 935-2211

Last updated:
November 16, 2017

AbbVie

We’re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail

NORTH CHICAGO, Ill., Nov. 15, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Evercore ISI Biopharma Catalyst/Deep Dive Conference on Wednesday, November 29, 2017. Bill Chase, executive vice president and chief financial officer, will present at 7 a.m. Central time.

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVieAbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience.  In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.

SOURCE AbbVie

Contact(s)
AbbVie 
Media
Adelle Infante
adelle.infante@abbvie.com
(847) 938-8745
AbbVie 
Investors
Liz Shea
liz.shea@abbvie.com
(847) 935-2211

Last updated:
November 16, 2017

AbbVie

We’re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail